Nav: Home

Cancer relapse linked to body's own immune system

October 16, 2017

Cancer cells that survive after treatment may use the body's own immune system to wake themselves up and fuel their growth, a new study shows.

The research sheds new light on how the immune system loses its ability to keep cancer in check, leading to the patient relapsing.

And the researchers found immunotherapy could be effective at preventing relapse, by getting the body's immune response back on track.

Scientists at The Institute of Cancer Research, London, with colleagues in Leeds, Surrey and the US, aimed to understand how a small number of cancer cells that resist treatment can turn deadly after lying dormant for long periods.

The researchers studied the immune response in mice to investigate how the cells of the immune system behaved before initial treatment, after treatment appeared to have worked, and when tumours returned.

The study is published today (Monday) in the journal Cancer Immunology Research and was funded by the European Research Council, the Richard M Schulze Family Foundation, the Mayo Foundation, Cancer Research UK, and the US National Institutes of Health.

Immune cells normally release signals that trigger inflammation in response to trauma or infection which, in some circumstances, can help the immune system kill cancer cells.

But the new research suggests these signals are subverted by leftover cancer cells after treatment, and used to drive their aggressive growth during relapse.

Crucially, the researchers showed that immunotherapies that target this response could either delay or prevent cancer returning in mice - suggesting that this approach could be effective in patients at risk of relapse.

Researchers found that a chemical signal called TNF-alpha switches in its effect from an anti-tumour agent that supports the immune response to eliminate cancer cells, to a new type of signal that promotes cancer relapse.

Resistant cells were also able to tell immune cells called natural killer cells to turn a blind eye, so that the relapsing cancer cells could grow unchecked.

Researchers found that the resistant cancer cells had high levels of a molecule called PD-L1 on their surface, which interacts with PD-1 on immune cells called T cells to tell them not to attack.

PD-1 is the target for highly successful immune checkpoint inhibitor drugs, and the researchers showed these treatments could delay or prevent relapse in mice.

Study co-author Professor Alan Melcher, Professor of Translational Immunotherapy at The Institute of Cancer Research, London, said:

"Our study finds the body's own immune system seems to play a crucial role when cancer relapses. The immune system goes from keeping cancer cells in check to awakening and feeding residual cells, while turning a blind eye to their growth.

"Excitingly, many of the methods employed by treatment-resistant tumours to re-grow and hide from the immune system can be blocked using existing immunotherapies. This idea is, in fact, supported by emerging data from clinical trials, showing that immunotherapies can reduce the risk of cancers coming back."

Study co-author Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, London, said:

"It is becoming increasing clear that the immune system is at the core of the puzzle of how we can treat cancer more effectively.

"This fascinating new study helps explain why sometimes a patient's immune system can be effective against cancer cells while at other times it is not. It also shows there is a lot more to learn about the nature of those cancer cells that lie dormant as a way of resisting the killing effects of cancer treatments. Changes must occur in these cells that make them better able to manipulate the immune system - and understanding this could open up new treatment options to prevent relapse."
-end-
For more information please contact Claire Hastings in the ICR press office on 020 7153 5380 or claire.hastings@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.

Notes to editors

The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

Institute of Cancer Research

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.